243
Mon, 7/31/2017,
2:00 PM -
3:50 PM
CC-Halls A&B
Contributed Poster Presentations: Biopharmaceutical Section — Contributed Poster Presentations
Biopharmaceutical Section
Chair(s): Jessi Cisewski, Yale University
17:
Event Rate Estimation Based on Blinded Time-To-Event Data to Verify Sample Size Calculation Assumptions
—
Youlan Rao, United Therapeutics Corporation, Durham, NC ; Suhyun Kang, North Carolina State University, Raleigh, NC ; Jody Cleveland, United Therapeutics Corporation, Durham, NC ; Chunqin Deng, United Therapeutics Corporation, Durham, NC
18:
Generalized Youden's Index to Derive the Optimal Thresholds for Discriminant Analysis
—
Kelly H. Zou, Pfizer Inc ; Ching-Ray Yu, Pfizer Inc ; Jason Pan, Pfizer Inc ; Dhaval Patel, Pfizer Inc ; Martin Carlsson, Pfizer Inc
19:
Sample Size Calculation in Clinical Trials with Binary Co-Primary Endpoints or Multiple Testing Procedures
—
Zuoshun Zhang, Celgene Corporation
20:
Survival Prediction in Early-Stage Lung Cancer via Bayesian Model Averaging of Nonparametric Accelerated Failure Time Models
—
Kijoeng Nam, Merck ; Nicholas Henderson, Johns Hopkins University ; Dai Feng, Merck
21:
An Evaluation of Multiple Imputation Methods for Hierarchical Data
—
Takayuki Abe, Keio University School of Medicine ; Manabu Iwasaki, Seikei University
22:
A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades
—
Sungjin Kim, Cedars-Sinai Medical Center ; Marcio Diniz, Cedars Sinai Medical Center ; Mourad Tighiouart, Cedars-Sinai Medical Center
23:
Constrained Longitudinal Model for Analyzing Pre- and Post-Treatment Count Data
—
Yongming Qu, Eli Lilly and Company ; Junxiang Luo, Eli Lilly and Company ; Hong Zhao, Abbott Laboratories
24:
A Curtailed Design for Selecting the t Best Among Bernoulli Treatments and a Control
—
Mingyue Wang, Syracuse University ; Pinyuen Chen, Syracuse University
25:
Two-Stage Design for Phase II Cancer Clinical Trials with Multiple Endpoints
—
Hui Gu, Rutgers University ; Yong Lin, Rutgers ; Weichung Joe Shih, Rutgers School of Public Health ; Yaqun Wang, Rutgers ; Kejian Liu, Celgene
26:
Drug Combination Dose Allocation Using Minimal Sets and Coherence in Partially Ordered Sets in Phase I Cancer Trials
—
Galen Cook-Wiens, Cedars Sinai Medical Center ; Matthieu Clertant, Cedars-Sinai Medical Center ; Mourad Tighiouart, Cedars-Sinai Medical Center
27:
Interim Analysis with Short-Term and Long-Term Endpoint in Adaptive Group Sequential Design
—
Lin Pan, ICON PLC ; Jill Stankowski, ICON PLC
28:
Sample Size Calculation Based on Finite Mixture Model
—
Zejiang Yang, INC Research
29:
Local Odds Ratio Is More Efficient Than Correlation Coefficient For Modeling Longitudinal Ordinal Data
—
Xinkai Zhou, Statistics Core@UCLA ; Ronghui Xu, University of California, San Diego ; David Elashoff, University of California, Los Angeles
30:
Modeling Excess Zeroes in an Integrated Analysis of Vaccine Safety
—
Roger Maansson, Pfizer Inc. ; David Radley, Pfizer Inc. ; Qin Jiang, Pfizer Inc. ; Scott Patterson, Pfizer Inc. ; Judith Absalon, Pfizer Inc. ; John Perez, Pfizer Inc.
31:
Using an Onset-Anchored Bayesian Hierarchical Model to Improve Predictions for Amyotrophic Lateral Sclerosis Disease Progression
—
Alex Karanevich
32:
What Is the Best Design for Dose-Finding Trials with Small Number of Doses?
—
Lai Wei ; Julie Stephens, The Ohio State Univeristy ; Vedat Yildiz, The Ohio State University ; Marilly Palettas, The Ohio State University ; Songzhu Zhao, The Ohio State University ; Xueliang Pan, The Ohio State Univeristy
33:
An R Shiny Foundation for Standardized Clinical Review Tools
—
Jimmy Wong, FDA
34:
Analysis Timing in Oncology Immunotherapy Trials with a Late Separation of Overall Survival Curve
—
Shu-Chih Su, Merck
35:
Analysis of Adverse Event Relationships in Clinical Trials Using JMP
—
Anastasia Dmitrienko ; Kelci Miclaus, JMP Life Sciences, SAS Institute Inc. ; Richard C. Zink, JMP Life Sciences, SAS Institute, Inc.
37:
Sample Size Re-Estimation and Other Midcourse Adjustments with Sequential Parallel Comparison Design
—
Rachel Silverman, University of North Carolina ; Anastasia Ivanova, UNC at Chapel Hill
38:
A Modified LOCF-PMM Method with Multiple Imputation for Handling Missing Data in Longitudinal Studies
—
Busola Sanusi, The University of North Carolina at Chapel Hill ; Kenneth Liu, Merck & Co. ; Gregory Golm, Merck & Co., Inc.
40:
A Simulation Study to Evaluate the Performance of Different Exposure Response Analyzes Using Concentration-QTc Data
—
Dalong Huang, FDA
41:
Sensitivity Analysis of Andersen-Gill Model
—
Dongmei Lan ; Jill Stankowski, ICON PLC
42:
Design of Drug Combination Early Phase Cancer Trials Using Time to Toxicity Data
—
Marcio Diniz, Cedars Sinai Medical Center ; José Jimenez, Politecnico di Torino ; Andre Rogatko, Cedars Sinai Medical Center ; Mourad Tiguiouart, Cedars Sinai Medical Center
43:
Emax Modeling for Assessing Dose-Response Relationships Using JMP
—
Beibo Zhao, University of North Carolina at Chapel Hill ; Richard C. Zink, JMP Life Sciences, SAS Institute, Inc.
46:
Quantitative Analysis of Spreading Defects and Response to Therapeutics in Lowe Syndrome
—
Brittany Griggs, Purdue University ; Swetha Ramadesikan, Purdue University ; Ruben Claudio Aguilar, Purdue University
48:
Comparing Two Correlated ROC Curves: a Generalized Pivotal Quantity Approach
—
Yonggang Zhao, Skyview Research ; Qianqiu Li, Johnson and Johnson
49:
dECiDe: software developed by Cytel and AstraZeneca for early clinical study design
—
Patrick D. Mitchell, Early Clinical Development AstraZeneca ; Dominic Magirr, AZ IMED Biotech Unit, ECD Biometrics ; Elizabeth Pilling, AZ IMED Biotech Unit, ECD Biometrics ; James Matcham, AZ IMED Biotech Unit, ECD Biometrics ; Jaydeep Bhattacharyya, Cytel Inc. ; Charles Liu, Cytel Inc.